Annotation Detail
Information
- Associated Genes
- BRCA2
- Associated Variants
-
BRCA2 LOSS-OF-FUNCTION
BRCA2 LOSS-OF-FUNCTION - Associated Disease
- pancreatic cancer
- Source Database
- CIViC Evidence
- Description
- In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of 77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.
- Variant Origin
- germline
- Variant Origin
- Rare Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5933
- Gene URL
- https://civic.genome.wustl.edu/links/genes/7
- Variant URL
- https://civic.genome.wustl.edu/links/variants/186
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Pancreatic Cancer
- Evidence Direction
- Supports
- Drug
- Veliparib,Cisplatin,Gemcitabine
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 29338080
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cisplatin | Sensitivity | true |
| Gemcitabine | Sensitivity | true |
| Veliparib | Sensitivity | true |